Prof. Dr. Alexander Haug is a specialist in Nuclear Medicine with more than 20 years of clinical experience, focusing on thyroid disorders, metastatic prostate cancer, and neuroendocrine tumors.
His clinical expertise includes:
-
177Lu-DOTATATE PRRT
-
225Ac-DOTATATE
-
177Lu-PSMA radioligand therapy
-
selected 225Ac-PSMA therapy
-
161Terbium-PSMA therapy
Patients from Austria and from aboard are welcome.
Experience & Expertise
-
20+ years clinical experience in Nuclear Medicine
-
1.000+ 177Lu-DOTATATE treatments
-
500+ 177Lu-PSMA treatments
-
160+ scientific publications
Individual treatment assessment
Thyroid disorders
Diagnosis and treatment of thyroid disorders, including thyroid nodules, autoimmune thyroid disease and thyroid cancer
Prostate Cancer
PSMA PET/CT, 177Lu-PSMA and selected 225Ac- and 161Tb-PSMA therapies
Neuroendocrine tumors
Somatostatin receptor imaging, PRRT with 177Lu-DOTATATE and selected 225Ac-DOTATATE therapies
International Patients
Specialist assessment and treatment in Vienna
Patients from outside Austria can submit their medical records for an initial assessment before travelling to Vienna.
How it works
-
Submit your records: Send us your medical reports, imaging and relevant laboratory results.
-
Individual assessment: Your case is reviewed to determine whether a consultation or radionuclide therapy may be appropriate.
-
Consultation: We discuss your diagnosis, previous treatments and possible treatment options.
-
Treatment & follow-up: If indicated, treatment is arranged in Vienna with appropriate follow-up.
About Prof. Dr. Alexander Haug
I am a specialist in Nuclear Medicine with more than two decades of clinical and academic experience.
I have worked at major university hospitals in Germany and Austria, with a particular focus on radionuclide therapy and the diagnosis and treatment of neuroendocrine tumors and prostate cancer.
My clinical work combines extensive experience in nuclear medicine with an individualized approach to each patient.
Looking for a second opinion?
If you have been diagnosed with metastatic prostate cancer or a neuroendocrine tumor and are considering radionuclide therapy, an independent specialist assessment may help clarify whether a treatment such as PRRT, 177Lu-PSMA or a 225Ac-based therapy could be appropriate in your individual situation.
Radionuclide Therapy Is More Than a Treatment
Radionuclide therapy is not simply a matter of administering a radiopharmaceutical.
The important question is whether a particular treatment is appropriate for you, at this particular stage of your disease.
I personally review your medical history, PET/CT imaging, pathology and previous treatments to assess:
-
whether radionuclide therapy is appropriate
-
which radionuclide and treatment strategy may be suitable
-
whether treatment should be given now or at a later stage
-
which alternatives should be considered
-
how previous radionuclide treatments affect future treatment decisions
The aim is an individual, evidence-based assessment rather than a standardized treatment approach.